Abstracts Archive - Page 462 of 2605 - ACR Meeting Abstracts

Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Luis Vega Sevilla¹, Oscar E. Alvarez-González², Janett Riega-Torres³, Cassandra Michele Skinner-Taylor³, Diana Carolina Rubio Torres⁴, Lucio Vera Cabrera⁵, Dionicio A. Galarza-Delgado⁶, Jesus Alberto Cardenas-De la Garza⁷, Rodrigo J. Castillo-de la Garza⁵, Mario Alberto Aguilera Valenciano⁵, wendy Escalante⁵ and Hector Guerra⁸, ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Faculty of Medicine and University Hospital Dr. José Eleuterio González, UANL, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico, ⁷Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁸Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…
Abstract Number: 2337 • ACR Convergence 2023
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 2342 • ACR Convergence 2023
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Aida Santos da Costa¹, Thomas Dörner², Andrea Grioni¹, Alexandre Avrameas¹, Ulrike Sommer¹, Rainer Hillenbrand¹, Valeria De Luca¹, Enrico Ferrero¹, Andre Nogueira da Costa¹, Isabelle Isnardi¹ and Stephen J Oliver¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany
Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 2335 • ACR Convergence 2023
Defining a Basket Population for ANA+ Arthritis Trials
Jack Arnold¹, Md Yuzaiful Md Yusof¹, Lucy Carter², Zoe Wigston¹ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²University of Leeds, Hartlepool, United Kingdom
Background/Purpose: Musculoskeletal (MSK) manifestations are common in systemic lupus erythematosus (SLE) and other ANA-associated rheumatic musculoskeletal diseases (ANA-RMDs). Presently clinical trials recruit patients from individual…
Abstract Number: 2341 • ACR Convergence 2023
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Javier Loricera³, Clara Moriano Morales⁴, Carmen Lasa⁵, Vanesa Calvo Río⁶, Javier Narvaez⁷, Pablo Ignacio Navarro Guerra⁸, Ivette Casafont-Sole⁹, Judit Font Urgelles¹⁰, Adela Gallego¹¹, Irene Carrión-Barberà¹², Patricia Quiroga¹³, Santos Castañeda¹³, Angel Garcia-Aparicio¹⁴, Joaquin Maria Belzunegui Otano¹⁵, Juan Ramon De Dios¹⁶, Marta López¹⁷, Samuel Hernandez¹⁸, Sergi Heredia Martin¹⁹, Aaron Fariñas²⁰, Francisco Navarro²¹, Jorge Juan Fragio²², Carmen Escudero²³, Rafaela Ortega Castro²⁴, Leticia del Olmo Perez²⁵, Valvanera Pinillos²⁶, Eztizen Labrador²⁶, Mamen Ortega²⁷, Patricia Castro Pérez²⁷, Juan Maria Blanco-Madrigal²⁸, Marcos Paulino²⁹, María Ángeles Matías³⁰, Enrique Calvo-Aranda³¹, Cilia Peralta³², Silvia García³³, Jordi Camins-Fàbregas³⁴, Marta Garijo Bufort³⁵, Dolores Fabregas³⁶, Ana Urruticoechea³⁷, Miguel Medina Malone³⁸, Piter Jose Cossio Jimenez³⁹, Eva Perez-Pampin⁴⁰, Blanca Varas de Dios⁴¹, Carlos Vazquez Galeano⁴², Nuria Vegas Revenga⁴³, Olga Rusinovich⁴⁴, Emilio Giner-Serret⁴⁵, Jose Ramón lamúa⁴⁶ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario de León, León, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Hospital Universitario de Toledo, Toledo, Spain, ¹⁵University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Arava, Pamplona, Spain, ¹⁸Hospital Universitario Son Llatzer, Palma de Mallorca, Spain, ¹⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁰Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²¹Doctor. Rheumatology, Alicante, Spain, ²²Hospital General Universitario Valencia, Valencia, Spain, ²³Hospital Universitario de Valme, Sevilla, Spain, ²⁴Hospital Reina Sofía, Cordoba, Spain, ²⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ²⁶Hospital Universitario San Pedro, Logroño, Spain, ²⁷Hospital Universitario de Getafe, Getafe, Spain, ²⁸Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ²⁹Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ³⁰Hospital Universitario Infanta Leonor/Rheumatology Department, Madrid, Spain, ³¹Hospital Universitario Infanta Leonor, Madrid, Spain, ³²Hospital Clínico Lozano Blesa, Zaragoza, Spain, ³³Hospital Parc Taulí, Sabadell, Spain, ³⁴Hospital General de Granollers, Granollers, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital de Barbastro, Barbastro, Spain, ³⁷Hospital Can Misses, Ibiza, Spain, ³⁸Hospital Calahorra, Calahorra, Spain, ³⁹HOSPITAL REINA SOFIA, Tudela, Spain, ⁴⁰Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁴¹Santa Cristina Universitary Hospital, Madrid, Spain, ⁴²ZARAGOZA, Madrid, Spain, ⁴³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴⁴Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ⁴⁵Hospital Royo Villanova, Teruel, Spain, ⁴⁶Hospital Universitario del Henares, Alcalá de Henares, Spain
Background/Purpose: Belimumab (BLM) is a monoclonal antibody that inhibits B-lymphocyte stimulating factor (BlyS), approved in 2011 as a treatment for systemic lupus erythematosus (SLE). We…
Abstract Number: 2322 • ACR Convergence 2023
Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State
Yasmin Nariman¹, Juan Pablo Diaz Martinez², Kathleen Bingham¹, Patti Katz³ and Zahi Touma⁴, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³University of California San Francisco, San Rafael, CA, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression is one of the most common neuropsychiatric disorders in patients with SLE. The Centre for Epidemiologic Studies Depression Scale (CES-D) has been used…
Abstract Number: 2319 • ACR Convergence 2023
Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Clara Moriano Morales¹, Jaime Calvo- Alén², Iñigo Rúa-Figueroa³, MARIA ELVIRA DIEZ ALVAREZ¹, Cristina Bermúdez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Esther Uriarte Isacelaya¹³, carlos Marras Fernández-Cid¹⁴, Carlos Montilla-Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, PALOMA VELA¹⁹, Alina Boteanu²⁰, Javier Narvaez²¹, Victor Martinez-Taboada²², Blanca Hernández-Cruz²³, Jose Luis Andreu-Sánchez²⁴, José Ángel Hernández Beriain²⁵, Lorena Expósito²⁶, Raúl Menor-Almagro²⁷, Mónica Ibáñez-Barceló²⁸, Ivan Castellvi²⁹, Carles Galisteo³⁰, Enrique Raya³¹, Víctor Quevedo-Vila³², Tomás Vazquez-Rodriguez³³, jesús Ibáñez³⁴ and Jose-Maria Pego-Reigosa³⁵, ¹Rheumatology, Hospital Universitario de León, León, Spain, ²Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Bioaraba Research Unit, Vitoria, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Private Practice, Barcelona, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Spanish Health Care Service, Bilbao, Spain, ¹²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁵Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ¹⁶Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁸Rheumatology, Hospital Ourense, Ourense, Spain, ¹⁹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁰Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ²⁴Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Rheumatology, Hospital de Canarias, Tenerife, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ³⁰Hospital Universitario Parc Taulí, Sabadell, Spain, ³¹Rheumatology, Hospital San Cecilio, Granada, Spain, ³²Rheumatology, Hospital Monforte de Lemos, Lugo, Spain, ³³Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³⁴Rheumatology, Hospital Ribera Povisa, Vigo, Spain, ³⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences. We need to…
Abstract Number: 2348 • ACR Convergence 2023
Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Jinoos Yazdany¹, Kenji Oku², Luciana Seguro³, Paula Curtis⁴, Yoshifumi Inagaki⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ²Kitasato University School of Medicine, Department of Rheumatology and Infectious Diseases, Kanagawa, Japan, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Rheumatology Division, Universidade de Sao Paulo, São Paulo, Brazil, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Brentford, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Rheumatology Unit, Department of Medicine, Padova, Italy
Background/Purpose: BEL-treated patients (pts) in clinical trials and long-term extension (LTE) studies1-7 experienced comparable incidence of infections versus those treated with standard therapy (ST) alone…
Abstract Number: 2314 • ACR Convergence 2023
Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus
Emma Materne¹, Baijun Zhou¹, Hyon K. Choi², Yuqing Zhang³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Adolescent-onset SLE is associated with more severe disease than adult-onset SLE, but young adults may also experience adverse outcomes. We sought to compare disease…
Abstract Number: 2334 • ACR Convergence 2023
Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Ronald van Vollenhoven¹, Eric Morand², Richard A. Furie³, Kenneth Kalunian⁴, Raj Tummala⁵, Gabriel Abreu⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁶, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴University of California San Diego, La Jolla, CA, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, remission is an established therapeutic goal associated with reduced damage accrual and flares, and improved health-related quality of life.1 Here,…
Abstract Number: 2346 • ACR Convergence 2023
SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Zahi Touma¹, Cristina Arriens², Christine Henning³, Angela Carroll³, Paula Curtis⁴, Roger A. Levy⁵ and William Stohl⁶, ¹University of Toronto, Toronto, ON, Canada, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁶University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: A key treatment goal for patients (pts) with SLE is to reduce use of CS, due to their association with organ damage.1 BEL is…
Abstract Number: 2325 • ACR Convergence 2023
Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Emily Littlejohn¹, Lingxuan Kong², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear antibodies (ANAs) are a hallmark of systemic lupus erythematosus (SLE) and also a marker of subclinical autoimmunity. While a seminal study using the…
Abstract Number: 2321 • ACR Convergence 2023
Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort
CORAL Mourino Rodriguez¹, Jose-Maria Pego-Reigosa², Iñigo Rúa-Figueroa³, Francisco Rubino⁴, Iñigo Hernández-Rodríguez⁵, Raúl Menor-Almagro⁶, Esther Uriarte Isacelaya⁷, Eva Tomero Muriel⁸, TAREK CARLOS SALMAN MONTE⁹, MARIA IRENE CARRION BARBERA⁹, Maria Galindo¹⁰, Esther Rodriguez almaraz¹⁰, Norman Jiménez¹¹, Luis Ines¹² and Irene Altabas Gonzalez¹³, ¹Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁵Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁷Hospital Universitario de Donostia, Donostia, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ¹²Centro Hospitalar e Universitario de Coímbra, Coimbra, Portugal, ¹³Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: There is no information available regarding whether the patient's perception of disease activity aligns with current definitions of DORIS 2021 remission and Lupus Low…
Abstract Number: 2326 • ACR Convergence 2023
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Emily Littlejohn¹, Salem Almaani², Vanessa Birardi³, Ernie Yap⁴ and Christopher Collins⁵, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Medical Center, Columbus, OH, ³Aurinia Pharmaceuticals Inc, Edmonton, AB, Canada, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁵Formerly Aurinia Pharmaceuticals Inc., Copenhagen, Denmark
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…
Abstract Number: 2333 • ACR Convergence 2023
Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial
Ioana Cutcutache¹, Alex Powlesland¹, Andrew Skelton¹, Yunyun Sun¹, Matthew Page¹, George Stojan², Peter Lipsky³, Ania Skowera¹ and Christian Stach⁴, ¹UCB Pharma, Slough, United Kingdom, ²UCB, Baltimore, MD, ³AMPEL BioSolutions, Charlottesville, VA, ⁴UCB Pharma, Monheim am Rheim, Germany
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].